ImmuPharma plc

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:16 2024-06-28 EDT			5-day change	1st Jan Change
2.08 ^GBX	-2.35%		-6.09%	+24.78%

06-05	EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	AN
06-05	ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ImmuPharma PLC Announces Retirement of Robert Zimmer, President & Chief Science Officer

May 24, 2021 at 02:00 am

ImmuPharma PLC announced that Dr. Robert Zimmer, President & Chief Science Officer has confirmed to the Company that he will not be seeking re-election at the forthcoming Annual General Meeting scheduled for 28 June 2021 and will be retiring from ImmuPharma PLC and leaving the Board with effect from then.

Latest news about ImmuPharma plc

EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	06-05	AN
ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	06-05	CI
Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	04-29	CI
Immupharma jumps amid new IP strategy for P140 technology platform	04-02	AN
ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	04-02	CI
Incanthera says first order from skincare deal doubles	03-25	AN
Stocks make tepid start to new week	03-25	AN
AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss	03-25	AN
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up	03-06	AN
EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows	12-19	AN
Immupharma Decides to Move Directly to Late-stage Trial of Lupus Therapy	12-19	MT
ImmuPharma Appoints Contract Research Organization for Late-stage Lupuzor Trial	12-19	MT
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm	12-19	CI
Incanthera signs skincare stocking deal, raises GBP1 million	12-18	AN
ImmuPharma plc Announces Executive Appointments	11-09	CI
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	11-07	CI
RA International loss narrows as revenue grows	23-09-07	AN
British Biopharmaceutical Company ImmuPharma Closes Retail Offer of New Shares	23-09-07	MT
FTSE 100 Ends Negative Month on Subdued Note	23-08-31	DJ
ImmuPharma Targets GBP2 Million Equity Raise; Stock Sinks 12%	23-08-31	MT
ImmuPharma launches GBP2 million fund raise as interim loss narrows	23-08-31	AN
Earnings Flash (IMM.L) IMMUPHARMA Reports H1 Revenue GBP69,959	23-08-31	MT
Earnings Flash (IMM.L) IMMUPHARMA Posts H1 Loss GBX-0.25	23-08-31	MT
ImmuPharma plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
ImmuPharma agrees 12 month extension to Incanthera warrant instrument	23-08-21	AN

Chart ImmuPharma plc

Duration

Period

More charts

Company Profile

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUPHARMA PLC	+24.78%	10.95M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research